Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.  Randhawa PA, Brar R, Nolan S.  CMAJ. 2020 Jan 20;19…

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.  Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P.  Addict Sci Clin Pract. 2020 Jan 15;15(1):2…

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.  Seguí HA, Melin K, Quiñones DS, Duconge J.  J Transl Genet Genom. 2020;4:263-277. doi: 10.20517/jtgg.2020.35. Epub 2020 Jul 30. PMID: 33274315;…

Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine.  Parsons G, Ragbir C, D'Agnone O, Gibbs A, Littlewood R, Hard B.  Subst Abuse Rehabil. 2020 Nov 2;11:41-47. doi…

Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department. Martin A, Butler K, Chavez T, Herring A, Wakeman S, Hayes BD, Raja A. West J Emerg Med. 2020 Nov 2;21(6):257-263. doi: 10.5811/westjem.2020.7.46079…

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders.  Bestepe EE, Tunali N, Sarıdoğan GE.  Neuropsychiatr Dis Treat. 2020 Nov 12;16:2695-2705. doi: 10.2147/NDT.S276…